Clinical Trial Search

Primary: Reduction of HbA1c From Baseline — -1.29; -0.55; -0.34 Percent (%)

Primary: Number of Participants Who Had Access to, and Received the Intervention — 24 Participants

Primary: Proportion of Patients Maintaining Target Mean Arterial Pressure (MAP) (>60 mmHg) With no Open Label NE (Norepinephrine) — 0.0; 47.1; 0.0; 10.0 Percentage of patients

Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…

Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 962.728; 985.257 Nanogram per milliltre (ng/mL) — p=0.3125

Primary: Number of Patients Experiencing Dose-Limiting Toxicities — 1; 1; 0 Participants

Primary: To Determine Whether Exogenous OT Enhances Emotional Intelligence and Improves Performance on Measures of Social Cognition for Schizophrenia or Schizoaffective Patients…

Primary: Number of Participants Who Could Tolerate Each Dose Level — 25; 16; 12; 16 Participants

Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028

Primary: Objective Response Rate — 3; 19; 4; 57 Participants

Primary: Clinician Administered PTSD Scale Subscore D (Hyperarousal) — 25.59; 26.07; 21.20; 22.07 units on a scale — p=0.723

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: PSA Response Rate — 18 Participants

Primary: Assessment of Clinical Global Impression-change. — 3.0; 4.2; 2.7 units on a scale

Primary: Number of Participants With Adverse Events — 1; 3; 2 Participants